Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 14
Submit an article Journal homepage
939
Views
15
CrossRef citations to date
0
Altmetric
Original Articles

Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis

Zhixin Shenga Department of Hematology, Weifang People’s Hospital, Weifang, Shandong, ChinaView further author information
,
Shilei Songb Department of Emergency Neurology, Weifang People’s Hospital, Weifang, Shandong, ChinaView further author information
,
Miao Yuc Department of Stomatology, Weifang People’s Hospital, Weifang, Shandong, ChinaView further author information
,
Hongguang Zhuc Department of Stomatology, Weifang People’s Hospital, Weifang, Shandong, ChinaView further author information
,
Anran Gaod Weifang Medical University, Weifang People's Hospital, Weifang, Shandong, ChinaView further author information
,
Weijie Gaod Weifang Medical University, Weifang People's Hospital, Weifang, Shandong, ChinaView further author information
,
Xuehong Rana Department of Hematology, Weifang People’s Hospital, Weifang, Shandong, ChinaView further author information
&
Da Huoe Department of Oncology, Weifang People's Hospital, Weifang, Shandong, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 3432-3439 | Received 21 May 2020, Accepted 07 Aug 2020, Published online: 30 Aug 2020

References

  • Piccirillo JF, Vlahiotis A, Barrett LB, et al. The changing prevalence of comorbidity across the age spectrum. Crit Rev Oncol Hematol. 2008;67(2):124–132.
  • Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. Lancet. 2018;391(10129):1524–1537.
  • Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–1110.
  • Goede V, Fischer K, Dyer MJ, et al. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities:final survival analysis of the CLL11 study. HemaSphere. 2018;2(S1):30.
  • Eichhorst B, Robak T, Montserrat E, et al. Appendix 6: chronic lymphocytic leukaemia: eUpdate published online September 2016. Ann Oncol. 2016;27(suppl 5):v143–v144. http://www.esmo.org/Guidelines?haematological-Malignancies.
  • National Comprehensive Cancer Network. Chronic lymphocytic leukemia/small lymphocytic leukemia, version 2. 2019; [cited 2020 Aug 17]. Available from:https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf.
  • Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–1291.
  • Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43–56.
  • Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–2236.
  • Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33(5):607–617.
  • Byrd JC, Gribben JG, Peterson BL, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006;24(3):437–443.
  • Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123(21):3247–3254.
  • Thompson PA, Tam CS, O’Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long­term disease­free survival in IGHV­mutated chronic lymphocytic leukemia. Blood. 2016;127(3):303–309.
  • Hallek M, Fischer K, Fingerle­Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open­label, phase 3 trial. Lancet. 2010;376(9747):1164–1174.
  • Eichhorst B, Fink AM, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928–942.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.